Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at ... FDA and has called for ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

GSK confirmed this morning that the disappointing ... that covers branded medicines pricing and access. The AI effect in pharma commercial strategy: From data to re... Discover how AI is ...

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...